This observation is consistent with previous findings in breast cancer where HR‐deficient breast cancers, particularly BRCA2‐mutant tumors, were more likely to respond to lurbinectedin than BRCA1/2 wild‐type tumors (Cruz et al, 2018). This evidence concerns the gene BRCA2 and breast carcinoma.